 |
|
|
| |
GS-7340 25 mg and 40 mg Demonstrate Greater Antiviral Activity Compared with TDF 300 mg in a 10-Day Monotherapy Study of HIV-1 Infected Patients
|
| |
| |
Reported by Jules Levin
19th Conference on Retroviruses and Opportunistic Infections
March 7, 2012
PJ Ruane1, E DeJesus2, D Berger3, M Markowitz4,
UF Bredeek5, C Callebaut6, L Zhong6,
S Ramanathan6, MS Rhee6, K Yale6
1Peter J Ruane MD Inc., Los Angeles, CA; 2Orlando Immunology Center,
Orlando, FL; 3Northstar Healthcare, Chicago, IL; 4Aaron Diamond AIDS
Research Center, New York, NY; 5Metropolis Medical, San Francisco, CA;
6Gilead Sciences, Foster City, CA
|
| |
|
|
|
|
|
